Qube Research & Technologies (QRT)
UTHR icon

Qube Research & Technologies (QRT)’s United Therapeutics UTHR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127M Buy
233,639
+110,198
+89% +$62.1M 0.12% 219
2026
Q1 		$73.2M Buy
123,441
+25,137
+26% +$12.5M 0.08% 307
2025
Q4 		$47.9M Buy
98,304
+68,705
+232% +$32M 0.05% 515
2025
Q3 		$12.4M Sell
29,599
-121,496
-80% -$40.9M 0.01% 1185
2025
Q2 		$43.4M Sell
151,095
-31,495
-17% -$9.41M 0.04% 525
2025
Q1 		$56.3M Buy
182,590
+72,247
+65% +$24.8M 0.07% 370
2024
Q4 		$38.9M Buy
110,343
+56,530
+105% +$20.8M 0.05% 467
2024
Q3 		$19.3M Buy
53,813
+22,118
+70% +$7.47M 0.03% 691
2024
Q2 		$10.1M Sell
31,695
-152,962
-83% -$40.5M 0.02% 916
2024
Q1 		$42.4M Sell
184,657
-20,587
-10% -$4.65M 0.07% 346
2023
Q4 		$45.1M Buy
205,244
+121,279
+144% +$28M 0.09% 288
2023
Q3 		$19M Buy
83,965
+4,245
+5% +$978K 0.05% 429
2023
Q2 		$17.6M Sell
79,720
-96,447
-55% -$21.4M 0.06% 371
2023
Q1 		$39.5M Buy
176,167
+31,211
+22% +$7.69M 0.17% 129
2022
Q4 		$40.3M Buy
144,956
+77,946
+116% +$19.7M 0.22% 109
2022
Q3 		$14M Buy
+67,010
New +$15M 0.08% 325
2022
Q2 		– Sell
-15,557
Closed -$2.79M – 3159
2022
Q1 		$2.79M Buy
+15,557
New +$2.96M 0.02% 697
2021
Q4 		– Sell
-66,113
Closed -$12.2M – 2990
2021
Q3 		$12.2M Buy
66,113
+51,904
+365% +$10.2M 0.15% 160
2021
Q2 		$2.55M Buy
14,209
+6,505
+84% +$1.24M 0.03% 619
2021
Q1 		$1.29M Buy
+7,704
New +$1.28M 0.02% 756
2020
Q4 		– Sell
-48,259
Closed -$4.87M – 2230
2020
Q3 		$4.87M Buy
48,259
+4,995
+12% +$548K 0.07% 364
2020
Q2 		$5.24M Buy
+43,264
New +$4.87M 0.08% 336
2018
Q4 		– Sell
-1,440
Closed -$184K – 873
2018
Q3 		$184K Buy
1,440
+1,008
+233% +$125K 0.02% 536
2018
Q2 		$49K Buy
+432
New +$47.5K 0.03% 528

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Qube Research & Technologies (QRT)'s UTHR Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its United Therapeutics (UTHR) stake by 89% in Q2 2026, buying an estimated $62.1M and bringing the position to 233,639 shares worth $127M. The position accounts for 0.12% of the portfolio, ranked #219.

Qube Research & Technologies (QRT) first reported a position in UTHR in Q2 2018 and has held it in 24 quarters since. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Qube Research & Technologies (QRT) held 233,639 shares of United Therapeutics worth $127M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 110,198 United Therapeutics shares in Q2 2026, an estimated $62.1M.
  • United Therapeutics made up 0.12% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #219 holding.
  • Qube Research & Technologies (QRT) first reported a position in United Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.